Long-acting Exendin-9-39 and its application in the treatment of hypoglycemia and as a drug for treating hypoglycemia

By linking fatty acid groups to the side chain of Exendin-9-39, AR-GLP1R-01 and AR-GLP1R-02 were designed as GLP-1 receptor antagonists, solving the problem of the short half-life of Exendin-9-39 and achieving long-acting inhibition of insulin secretion, raising blood glucose, and treating congenital hyperinsulinemia.

CN116606367BActive Publication Date: 2026-11-10NANJING SHENG DE RUI ER MEDICINE TECH CO LTD +2
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202210611291.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-05-31
Publication Date
2026-11-10
Estimated Expiration
2042-05-31

AI Technical Summary

Technical Problem

The existing Exendin-9-39 has a short half-life, requires a large daily dose and continuous administration, making it difficult to effectively treat congenital hyperinsulinemia-induced hypoglycemia.

Method used

Two Exendin-9-39 derivatives, AR-GLP1R-01 and AR-GLP1R-02, were designed. By attaching fatty acid groups to their side chains, the stability of the compounds and their metabolic time in vivo were improved. As GLP-1 receptor antagonists, they inhibit insulin secretion and increase blood glucose.

Benefits of technology

AR-GLP1R-01 and AR-GLP1R-02 significantly prolong the duration of action, effectively inhibit insulin secretion, increase blood glucose levels, and provide long-term treatment for hypoglycemia with a long duration of effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116606367B_ABST
    Figure CN116606367B_ABST
Patent Text Reader

Abstract

This invention discloses a long-acting Exendin-9-39 and its application as a GLP-1 receptor antagonist in the treatment of hypoglycemia, as well as its use as a drug for treating hypoglycemia. The long-acting Exendin-9-39 comprises AR-GLP1R-01 and AR-GLP1R-02, wherein AR-GLP1R-01 has the structure shown in Figure 2, and AR-GLP1R-02 has the structure shown in Figure 3. The long-acting Exendin-9-39 of this invention can inhibit insulin secretion by inhibiting GLP-1 receptors, thereby increasing blood glucose levels in a mouse model of hypoglycemia (SUR1 knockout mice), thus achieving a therapeutic effect on congenital hyperinsulinemic hypoglycemia (CHI). Furthermore, compared to Exendin-9-39, AR-GLP1R-01 and AR-GLP1R-02 of this invention have a longer half-life, a longer duration of action, and a significantly improved effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomedical technology, specifically, it relates to a long-acting Exendin-9-39 and its application as a GLP-1 receptor antagonist in the treatment of hypoglycemia and as a drug for treating hypoglycemia. Background Technology

[0002] Congenital hyperinsulinism (CHI) is primarily caused by gene mutations encoding pancreatic β-cell function, leading to excessive or inappropriate insulin secretion, increased blood insulin concentration, and thus persistent hypoglycemia. It is also known as neonatal persistent hyperinsulinemia-induced hypoglycemia (neonatal hypoglycemia). Congenital hyperinsulinemia is difficult to cure and easily causes hypoglycemia in young infants. It is characterized by persistent hypoglycemia and disproportionately high insulin levels, accompanied by low ketone bodies and hypolipidemia. The younger the infant, the greater the harm caused by hypoglycemia. Hypoglycemia is a dangerous condition; if not detected and treated promptly, it can cause seizures, lasting brain damage, and even death.

[0003] The most common and most severe subtype of CHI is congenital hyperinsulinemia (K-HI) caused by loss-of-function mutations in the ATP-dependent potassium channels (including the SUR1 and Kir6.2 subunits) of pancreatic β-cells. ATP -CHI), in children with this condition, the pancreatic β cells continuously and unregulatedly secrete large amounts of insulin, causing severe hypoglycemia, K ATP Children with CHI are not sensitive to diazoxide, and for many patients, surgical removal of the pancreas is the only option.

[0004] Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that assists and improves glucose-stimulated insulin secretion. GLP-1 analogs and inhibitors of GLP-1 degrading enzyme (DDP4) have been widely used as novel drugs in the treatment of type 2 diabetes. Because congenital hyperinsulinemia has the opposite pathogenesis to diabetes, GLP-1 receptor antagonists can be used to treat hypoglycemia. Previous studies have found that GLP-1 receptor antagonist (Exendin-9-39) can significantly increase blood glucose in a potassium channel (SUR1) knockout mouse model. Further clinical trials in patients have demonstrated the drug's effectiveness in hypoglycemic patients. Related articles have been published in JBC (2008) and Diabetes (2012).

[0005] Exendin-9-39 is a small peptide containing multiple amino acid residues, with the molecular formula C0. 149 H234 N 40 O 47 S, with a molecular weight of 3369.8, is derived from Exendin-4 by deleting the first 8 amino acid residues from its N-terminus. Exendin-4 is an activator of the GLP-1 receptor, primarily promoting the binding of GLP-1 to the receptor and inducing cAMP production, thus exerting effects similar to GLP-1: increasing glucose-dependent insulin secretion, inhibiting glucagon secretion, accelerating glucose clearance, delaying gastric emptying, inducing satiety, and suppressing appetite; it can also improve peripheral insulin resistance, etc. Exendin-9-39, lacking 8 amino acids, is a GLP-1 receptor inhibitor with completely opposite effects to Exendin-4. Its main function is as a GLP-1 receptor antagonist in animals, inhibiting pancreatic cAMP production by binding to the GLP-1 receptor, thereby blocking GLP-1, reducing insulin secretion, increasing glucagon secretion, and increasing appetite, etc.

[0006] However, due to the disadvantages of Exendin-9-39, such as its short half-life, large daily dosage, and need for continuous administration, two derivatives of Exendin-9-39, AR-GLP1R-01 and AR-GLP1R-02, were designed to increase the half-life, prolong the drug's metabolic time in the body, and reduce the dosage. Summary of the Invention

[0007] To address the aforementioned problems, this invention provides a long-acting Exendin-9-39 and its application as a GLP-1 receptor antagonist in the treatment of hypoglycemia, as well as its use as a drug for treating hypoglycemia. The long-acting Exendin-9-39 of this invention can inhibit insulin secretion by inhibiting GLP-1 receptors, thereby increasing blood glucose levels in a mouse model of hypoglycemia (SUR1 knockout mice), and thus achieving a therapeutic effect on congenital hyperinsulinemic hypoglycemia (CHI).

[0008] The objective of this invention and the technical problem it solves are achieved by the following technical solutions.

[0009] One aspect of the present invention provides a long-acting Exendin-9-39, the long-acting Exendin-9-39 comprising AR-GLP1R-01 and AR-GLP1R-02, wherein AR-GLP1R-01 has as Figure 2 The AR-GLP1R-02 has the structure shown, as described above. Figure 3 The structure shown.

[0010] The objectives of this invention and the technical problems it solves are also achieved by adopting the following technical solutions.

[0011] Another aspect of the present invention provides the use of long-acting Exendin-9-39 as a GLP-1 receptor antagonist in the treatment of hypoglycemia.

[0012] Preferably, the GLP-1 receptor antagonist is an inhibitor that inhibits the function of the GLP-1 receptor.

[0013] Preferably, the GLP-1 receptor antagonist contains long-acting Exendin-9-39, the concentration of which is between 0.1 μM and 13 μM.

[0014] Preferably, the long-acting Exendin-9-39 includes AR-GLP1R-01 and AR-GLP1R-02, wherein AR-GLP1R-01 has the following characteristics: Figure 2 The AR-GLP1R-02 described herein has the structure shown. Figure 3 The structure shown.

[0015] The objectives of this invention and the technical problems it solves are also achieved by adopting the following technical solutions.

[0016] Another aspect of the invention provides a medicament for treating hypoglycemia, said medicament comprising a GLP-1 receptor antagonist.

[0017] Preferably, the GLP-1 receptor antagonist is an inhibitor that inhibits the function of the GLP-1 receptor.

[0018] Preferably, the GLP-1 receptor antagonist contains long-acting Exendin-9-39.

[0019] Preferably, the long-acting Exendin-9-39 includes AR-GLP1R-01 and AR-GLP1R-02, wherein AR-GLP1R-01 has the following characteristics: Figure 2 The AR-GLP1R-02 described herein has the structure shown. Figure 3 The structure shown.

[0020] Preferably, the concentration of the long-acting Exendin-9-39 in the GLP-1 receptor antagonist is between 0.1 μM and 13 μM.

[0021] By employing the above technical solution, the present invention has at least the following advantages:

[0022] (1) The AR-GLP1R-01 and AR-GLP1R-02 of the present invention are obtained by attaching fatty acid groups to the side chain of Exendin-9-39. Compared with Exendin-9-39, these two compounds have better stability and significantly longer metabolism time in vivo.

[0023] (2) Based on the effects of Exendin-9-39 in reducing insulin secretion, increasing glucagon secretion, and increasing appetite, this invention provides two Exendin-9-39 derivatives, AR-GLP1R-01 and AR-GLP1R-02, as GLP-1 receptor antagonists in the treatment of hypoglycemia. The results show that AR-GLP1R-01 and AR-GLP1R-02 have similar effects to Exendin-9-39, and also inhibit the problem of excessive insulin secretion by pancreatic islets caused by ATP-dependent potassium ion channel loss of function mutation, thereby achieving the therapeutic purpose of raising blood glucose in CHI. Moreover, AR-GLP1R-01 and AR-GLP1R-02 have significantly prolonged action time and significantly improved efficacy.

[0024] (3) The present invention also provides a drug for treating hypoglycemia, wherein AR-GLP1R-01 or AR-GLP1R-02 is the main active substance, and the drug can effectively treat hypoglycemia and has a long duration of effect.

[0025] The above description is merely an overview of the technical solution of the present invention. In order to better understand the technical means of the present invention and to implement it in accordance with the contents of the specification, the preferred embodiments of the present invention are described in detail below. Attached Figure Description

[0026] Figure 1 It is the Exendin-9-39 structural formula;

[0027] Figure 2 It is an AR-GLP1R-01 structural design;

[0028] Figure 3 It is an AR-GLP1R-02 structural design;

[0029] Figure 4 This is a schematic diagram of CRISPR / Cas9 technology.

[0030] Figure 5 Perfusion experiment for isolating and culturing pancreatic islets;

[0031] Figure 6 For live experiments in SUR1-KO mice: changes in blood glucose levels before and 1 hour after subcutaneous injection of Exendin-9-39 or AR-GLP1R-01 on the first day of administration;

[0032] Figure 7 For in vivo experiments on SUR1-KO mice: blood glucose levels before administration on the second day after subcutaneous injection of Exendin-9-39 or AR-GLP1R-01;

[0033] Figure 8For in vivo experiments on SUR1-KO mice: blood glucose levels before and 1 hour after administration of Exendin-9-39 or AR-GLP1R-01 on the 4th day after subcutaneous injection of Exendin-9-39 or AR-GLP1R-01.

[0034] Figure 9 For in vivo experiments on SUR1-KO mice: Blood glucose levels before administration of Exendin-9-39 or AR-GLP1R-01 on day 4 after subcutaneous injection;

[0035] Figure 10 For the SUR1-KO mouse in vivo experiment: Blood glucose levels were measured 17 hours after the 4th day following subcutaneous injection of Exendin-9-39 or AR-GLP1R-01, starting at 5 pm and continuing until the morning of the 5th day.

[0036] Figure 11 Blood glucose levels at 16 and 24 hours after subcutaneous injection of Exendin-9-39 and AR-GLP1R-01 into SUR1-KO mice;

[0037] Figure 12 Perfusion experiment for isolating and culturing pancreatic islets;

[0038] Figure 13 For in vivo experiments on SUR1-KO mice: blood glucose changes before and 1 hour after subcutaneous injection of Exendin-9-39 or AR-GLP1R-02 on the first day of administration;

[0039] Figure 14 For in vivo experiments on SUR1-KO mice: blood glucose levels before and 1 hour after administration of Exendin-9-39 or AR-GLP1R-01 on the 4th day after subcutaneous injection of Exendin-9-39 or AR-GLP1R-01.

[0040] Figure 15 For the SUR1-KO mouse in vivo experiment: Blood glucose levels were measured 17 hours after the 4th day following subcutaneous injection of Exendin-9-39 or AR-GLP1R-01, starting at 5 pm and continuing until the morning of the 5th day.

[0041] Figure 16 HPLC chromatograms of Exendin-9-39 at different concentrations;

[0042] Figure 17 The standard curve for Exendin-9-39 concentration and the chromatogram of blood concentration detection after injection in SUR1-KO mice;

[0043] Figure 18 HPLC chromatograms of AR-GLP1R-01 at different concentrations;

[0044] Figure 19The standard curve for AR-GLP1R-01 concentration and the chromatogram of blood concentration detection in SUR1-KO mice after injection;

[0045] Figure 20 Chromatograms of AR-GLP1R-02 at different concentrations by HPLC;

[0046] Figure 21 The standard curve for AR-GLP1R-02 concentration and the chromatogram for blood concentration detection in SUR1-KO mice after injection. Detailed Implementation

[0047] To make the technical means, creative features, achieved objectives, and effects of this invention readily understandable, the technical solutions in the embodiments of this invention will be clearly and completely described below in conjunction with the embodiments of this invention. Obviously, the described embodiments are merely some embodiments of this invention, and not all embodiments. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.

[0048] The long-acting Exendin-9-39 according to the present invention is a derivative of Exendin-9-39, including AR-GLP1R-01 and AR-GLP1R-02, wherein AR-GLP1R-01 has the following properties: Figure 2 The AR-GLP1R-02 has the structure shown, as described above. Figure 3 The structure shown.

[0049] The application of the long-acting Exendin-9-39 as a GLP-1 receptor antagonist in the treatment of hypoglycemia according to the present invention, wherein the GLP-1 receptor antagonist is an inhibitor that inhibits the function of GLP-1 receptors. The GLP-1 receptor antagonist comprises long-acting Exendin-9-39, and the concentration of long-acting Exendin-9-39 is between 0.1 μM and 13 μM. Long-acting Exendin-9-39 comprises AR-GLP1R-01 and AR-GLP1R-02, wherein AR-GLP1R-01 has the following characteristics: Figure 2 The AR-GLP1R-02 described herein has the structure shown. Figure 3 The structure shown.

[0050] According to the present invention, a medicament for treating hypoglycemia comprises a GLP-1 receptor antagonist. The GLP-1 receptor antagonist is an inhibitor that inhibits the function of the GLP-1 receptor. The GLP-1 receptor antagonist comprises long-acting Exendin-9-39. Long-acting Exendin-9-39 comprises AR-GLP1R-01 and AR-GLP1R-02, wherein AR-GLP1R-01 has the following characteristics: Figure 2 The AR-GLP1R-02 described herein has the structure shown. Figure 3 The structure is shown. The concentration of long-acting Exendin-9-39 in GLP-1 receptor antagonists ranges from 0.1 μM to 13 μM.

[0051] Example 1: Preparation of AR-GLP1R-01 and AR-GLP1R-02

[0052] In this embodiment, AR-GLP1R-01 and AR-GLP1R-02 are Exendin-9-39, collectively referred to as long-acting Exendin-9-39.

[0053] The structure of Exendin-9-39 is as follows: Figure 1 As shown, its amino acid sequence is:

[0054] H-Asp-Leu-Ser-Lys-D-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

[0055] AR-GLP1R-01 and AR-GLP1R-02 in this embodiment are obtained by attaching the following structure I side chain to the lysine side chain at positions 12 and 27 of Exendin-9-39, the principle of which is to prolong the metabolic time of the drug itself in vivo.

[0056]

[0057] AR-GLP1R-01 and AR-GLP1R-02 in this embodiment were prepared by a third-party organization, Chengdu Shengnuo Biotechnology Co., Ltd.

[0058] Example 2: Basic technical principles and steps for creating SUR1 gene knockout mice

[0059] 1. Principle

[0060] Using CRISPR / Cas9 gene knockout technology, crRNA binds to tracrRNA (trans-activating RNA) via base pairing to form double-stranded RNA. This tracrRNA:crRNA binary complex guides the Cas9 protein to cleave double-stranded DNA at a specific site on the crRNA guide sequence target. At the site complementary to the crRNA guide sequence, the HNH nuclease domain of the Cas9 protein cleaves the complementary strand, while the Cas9 RuvC-like domain cleaves the non-complementary strand, thus achieving the function of knocking out the target gene and creating a gene knockout mouse model.

[0061] 2. Vector design, construction, and purification

[0062] Using the CRISPR Design tool from MIT (http: / / crispr.mit.edu / ), a pair of 20bp oligonucleotide sequences targeting the target DNA were designed based on the score to prepare sgRNA. Primers were then designed in this target region for subsequent gene identification in mice. The designed sequences were synthesized into PAGE products.

[0063] The synthesized two single-stranded oligonucleotide (sgRNA) sequences were annealed (at 95°C for 5 min, then allowed to cool to room temperature naturally) to form double-stranded DNA. These DNA sequences were then linked to a pGK1.1 linear vector using T4 DNA ligase to construct an sgRNA expression vector. The recombinant plasmid was transformed into DH5α competent cells. Positive clones were screened and identified by kanamycin resistance of the pGK1.1 linear vector and sequencing of the target DNA. Correct colony clones were selected, expanded, and then the plasmids were extracted for use as templates for in vitro transcription.

[0064] 3. In vitro transcription

[0065] The expression vector of sgRNA was linearized by DraI digestion, purified by phenol-chloroform extraction, dissolved in nuclease-free water as a template for in vitro transcription, and sgRNA was synthesized in vitro by T7 RNA polymerase according to the MEGAshortscript Kit (Ambion, AM1354).

[0066] 4. Microinjection of Cas9 / sgRNA

[0067] The transcribed sgRNA and Cas9 were mixed and the injection concentration was adjusted. The mixture was then microinjected into the cytoplasm of C57BL / 6 mouse zygotes using a TE2000U microinjector. The zygotes were then transferred into the uterus of pseudopregnant C57BL / 6 mice, and the F0 generation mice were awaited to be born.

[0068] 5. Identification of F0 mice

[0069] Five to seven days after the birth of F0 generation mice, the mice were marked by toe clipping, and DNA was extracted from the cut tail tissue by phenol-chloroform method. The DNA was identified according to the primers designed in the target region in the above experiment (1), and PCR positive samples were selected for sequencing.

[0070] 6. Heritability testing of F0 generation mice

[0071] F0 generation mice with correct PCR and sequencing results were mated with wild-type C57BL / 6 mice to produce F1 generation mice. The F1 generation mice were identified using the same identification method as the F0 generation mice. The resulting positive F1 generation heterozygous mice could be stably inherited.

[0072] 7. Abcc8 gene creation protocol

[0073] This model uses CRISPR / Cas9 technology to edit the Abcc8 gene. A schematic diagram illustrating the principle is shown below. Figure 4 As shown.

[0074] (1) Primer information:

[0075]

[0076] (2) PCR amplification system:

[0077] Reaction composition Volume (μL) gDNA template 2.0 <![CDATA[10×Taq Buffer(mg 2+ plus)]]> 2.0 dNTP mixture (10mM) 0.5 Primer mix (10μM) 0.5 Taq DNA polymerase (5 U / μL) 0.5 <![CDATA[Milli-Q H2O]]> To 20μL

[0078] (3) PCR amplification program

[0079]

[0080]

[0081] Example 3: Isolation, purification and culture of pancreatic islets from SUR1-KO mice

[0082] 1. The islet isolation and purification from SUR1-KO mice includes the following steps:

[0083] (1) After anesthetizing the mice, fix them on the surgical board, open the abdominal cavity, close the entrance of the bile duct into the duodenum with hemostatic forceps, and then inject 2 mg / mL collagenase solution into the bile duct with a 5 mL syringe and a 31.5 needle until the pancreas is fully inflated.

[0084] (2) After removing the pancreas, cleaning away the fat and non-pancreatic tissue, transfer the pancreas to a 50mL centrifuge tube, add 3mL of 2mg / mL collagenase solution, and shake in a 37℃ water bath for 4-5 minutes.

[0085] (3) After shaking, immediately add Hanks buffer to 50 mL in a 50 mL centrifuge tube, then centrifuge, remove the supernatant, add 5 mL of Histopaque-1119 solution to the remaining tissue precipitate, and shake to mix.

[0086] (4) Slowly add 5 mL of Histopaque-1077 solution, then slowly add 5 mL of Hanks buffer, and then centrifuge.

[0087] (5) Remove the islet tissue from the layered liquid space, pick up the purified islets under a dissecting microscope, wash with Hanks buffer and culture.

[0088] 2. Islet culture procedure in SUR1-KO mice:

[0089] 1. Preparation of RPMI 1640 culture medium: The following ingredients are included in milliliters: 10 parts glucose, 2 parts glutamine, 10 parts fetal bovine serum, 24 parts sodium bicarbonate, 100 units / mL penicillin, 10 μg / mL streptomycin, and pH adjusted to 7.2.

[0090] 2. The isolated and purified islets were cultured overnight in an incubator at 37°C, 5% CO2 and 95% humidity using RPMI 1640 medium.

[0091] Example 4: Examination of pancreatic islet perfusion and insulin secretion

[0092] (1) Reaction solution: Krebs buffer

[0093] A): 107g of NaCl dissolved in 1000mL of water.

[0094] B): KCl (5.96g) + NaHCO3 (32.256g) + MgCl2-6H2O (3.25g) are dissolved in 1000mL of water.

[0095] C): CaCl2-2H2O: 5.168g dissolved in 1000mL of water.

[0096] Krebs buffer:

[0097]

[0098] BSA (0.25%): 2.0g

[0099] HEPES: 1.906g (10mM)

[0100] (2) Preparation of stimulant solution

[0101] 30 mM KCl solution; amino acid mixture (AAM)

[0102] AAM (100mL):

[0103] amino acids Content (mg) amino acids Content (mg) alanine 155.7 Isoleucine 49.32 Arginine 157.6 Leucine 85 Aspartic acid 21.8 Lysine 270.2 Citrulline 65.16 Methionine 28.64 glutamic acid 70.128 ornithine 46.52 glycine 89.48 Phenylalanine 54.2 Histidine 48.422 proline 160.68 Serine 238.89 threonine 128.64 Valine 94.16 Tryptophan 60.44

[0104] (4) Islet counting: 120 islets were collected in islet chambers and placed in a 37°C constant temperature water bath.

[0105] (5) Place the prepared reaction solutions into a water bath (37°C), insert the corresponding injection tubes, and follow the instrument procedure:

[0106]

[0107] (6) Collect secreted insulin with Waters Fraction Collector. Take 10 μL of the solution after the islet stimulation experiment and transfer it into a 384-well plate. Add antibody according to the instructions of the HTRF insulin assay kit, shake to mix, and incubate at room temperature for 2 hours. Read the value using the HTRF program of BMG's Clariostar microplate reader. Calculate the hormone secretion value according to the standard curve. Confirm the effect of stimulants or drugs on insulin secretion by measuring insulin secretion.

[0108] Example 5: Animal experiments with long-acting Exendin-9-39

[0109] (1) Experimental animals: 41 SUR1-KO mice

[0110] (2) Experimental compounds: Exendin-9-39, AR-GLP1R-01 and AR-GLP1R-02;

[0111] (3) Experimental instrument: blood glucose meter

[0112] (4) Experimental Groups:

[0113] a. Experimental group 1: 10 SUR1-KO mice were injected with Exendin-9-39;

[0114] b. Experimental group 2: 10 SUR1-KO mice were injected with AR-GLP1R-01;

[0115] c. Experimental group 3: 10 SUR1-KO mice were injected with AR-GLP1R-02;

[0116] d. Control group: 10 SUR1-KO mice were injected with physiological saline.

[0117] (5) Experimental methods:

[0118] A. Exendin-9-39 and its two derivatives, AR-GLP1R-01 and AR-GLP1R-02, were taken out at -80℃ and dissolved in sterile physiological saline to a concentration of 108 μmol / L. The solutions were then aliquoted and stored at -80℃ for later use.

[0119] B. Administer subcutaneous injections of 2 μL / g body weight twice daily (10:00 AM and 5:00 PM). Blood glucose levels were measured before the first injection and 1 hour after injection on days 1, 2, and 4. The control group received saline solution.

[0120] C. After four consecutive days of treatment, on the fourth day, after a second injection, remove the mice's food and change their bedding. Water was provided but not stopped, and the mice were then fasted.

[0121] D. Measure blood glucose levels after fasting for 16 hours.

[0122] E. If it is a single-injection trial, the injection dosage and method are the same as described in A and B.

[0123] Example 6: Concentrations of Exendin-9-39, AR-GLP1R-01, and AR-GLP1R-02 in the serum of SUR1-KO mice Measurement

[0124] The concentrations of Exendin-9-39, AR-GLP1R-01, and AR-GLP1R-02 in the serum of SUR1-KO mice were detected by liquid chromatography.

[0125] (1) Experimental conditions:

[0126] A. Drug concentration: 1080 μmol / L

[0127] B. Injection method and dosage: C57BL / 6 mice were injected intraperitoneally with 2 μL / g body weight.

[0128] C. Blood collection time: 0.5h, 2h, 10h

[0129] D. Blood collection method: Blood was collected from the inner canthus of the mouse eye. 10 μL of DPP4 inhibitor was added to the blood and the mixture was allowed to stand. The serum was then centrifuged at 3000 r / min for 3 min at 4℃ and the supernatant was collected and stored at -20℃.

[0130] (2) Serum treatment:

[0131] After treating serum proteins with a serum:acetonitrile ratio of 1:1.5, the sample was filtered through a membrane to obtain the loading liquid.

[0132] (3) Experimental apparatus:

[0133]

[0134]

[0135] (4) Experimental instrument parameter settings:

[0136] Mass spectrometry parameters

[0137]

[0138] Chromatographic parameters

[0139]

[0140] Example 7 Experimental Results and Analysis

[0141] (I) Comparative Study of AR-GLP1R-01 and Exendin-9-39

[0142] 1. Study on the effects of Exendin-9-39 and AR-GLP1R-01 on isolated pancreatic islet function:

[0143] Figure 5 A perfusion experiment was conducted to isolate and culture islets of Langerhans, demonstrating the dynamic secretion of insulin. The stimulant was an amino acid mixture (AAM) with concentrations increasing from 0 to 12 mM; the islets were from SUR1 knockout mice. Figure 5 As shown, SUR1-KO mice exhibited elevated basal insulin secretion and were sensitive to insulin secretion stimulated by amino acid mixtures (AAM), consistent with previous findings. 100 nM Exendin-9-39 reduced excessive basal insulin secretion and AAM-stimulated insulin secretion, also consistent with previous results. AR-GLP1R-01 (100 nM) at the same concentration had similar effects to Exendin-9-39, significantly inhibiting both basal insulin and AAM-stimulated insulin secretion. This indicates that AR-GLP1R-01 and Exendin-9-39 have similar effects, both improving excessive basal insulin secretion and excessive insulin response to amino acid stimulation caused by impaired pancreatic ATP-dependent potassium channels.

[0144] 2. Animal experimental results of Exendin-9-39 and AR-GLP1R-01

[0145] In vivo animal studies were conducted using Exendin-9-39 and AR-GLP1R-01. The experimental design involved subcutaneous injection of Exendin-9-39 and AR-GLP1R-01 twice daily (10:00 AM and 5:00 PM) for 4 consecutive days, at a concentration of 216 pM / g body weight.

[0146] Figure 6 In vivo experiments in SUR1-KO mice: Subcutaneous injection of drugs (Exendin-9-39 or AR-GLP1R-01, dose: 216 pM / g body weight) was performed. Blood glucose changes were observed before and 1 hour after administration on the first day. Exendin-9-39 and AR-GLP1R-01 significantly increased blood glucose levels in SUR1-KO mice. Figure 6 As shown, compared with the blood glucose of SUR1-KO mice that did not receive any medication, AR-GLP1R-01 and Exendin-9-39 had the same effect 1 hour after injection, both significantly increasing blood glucose in the disease mouse model.

[0147] Figure 7For in vivo experiments on SUR1-KO mice: Subcutaneous injection of the drug (Exendin-9-39 or AR-GLP1R-01, dose: 216 pM / g body weight), blood glucose level on the second day after drug administration. Figure 7 The results showed that before administration on the morning of the second day, the baseline blood glucose level in the Exendin-9-39 treatment group was the same as that in the blank control group, and the effect of raising blood glucose was not sustained. However, the effect of AR-GLP1R-01 could be maintained until 10:00 a.m. on the second day (approximately 17 hours) after two injections on the first day. This indicates that AR-GLP1R-01 can improve blood glucose in the disease mouse model for a long time, and the effect can be maintained until the fourth day.

[0148] Figure 8 For in vivo experiments in SUR1-KO mice: Subcutaneous injection of the drug (Exendin-9-39 or AR-GLP1R-01, dose: 216 pM / g body weight), blood glucose levels before and 1 hour after administration on day 4. Figure 8 As shown, after three days of twice-daily administration, on the morning of the fourth day, the basal blood glucose level in the Exendin-9-39 group was the same as that in the control group. One hour after injection of Exendin-9-39, blood glucose still showed a significant increase, indicating that the short-term therapeutic effect of Exendin-9-39 can occur repeatedly. Compared with the Exendin-9-39 group and the control group, AR-GLP1R-01 not only maintained the elevated basal blood glucose level observed on the second day, but also had the ability to continue to raise blood glucose for a short period of time one hour after injection.

[0149] Figure 9 For in vivo experiments in SUR1-KO mice: Subcutaneous injection of the drug (Exendin-9-39 or AR-GLP1R-01, dose: 216 pM / g body weight), blood glucose level on day 4 before drug administration. Figure 9 The results showed that AR-GLP1R-01 significantly increased basal blood glucose in SUR1-KO mice, but Exendin-9-39 had no effect on improving basal blood glucose. This further confirms that AR-GLP1R-01 has a significantly better effect on long-term blood glucose elevation than Exendin-9-39.

[0150] Figure 10 For the SUR1-KO mouse in vivo experiment: The drug (Exendin-9-39 or AR-GLP1R-01, dose: 216 pM / g body weight) was administered subcutaneously. Blood glucose levels were recorded 17 hours after fasting, starting at 5 PM on day 4 and continuing until the morning of day 5. Figure 10As shown, after four days of twice-daily administration, AR-GLP1R-01 significantly increased basal blood glucose in SUR1-KO mice, but Exendin-9-39 did not improve fasting blood glucose. Meanwhile, AR-GLP1R-01 significantly improved fasting blood glucose in the treated mouse model. This indicates that the long-term effect of AR-GLP1R-01 is significantly superior to Exendin-9-39, while its short-term effect (1 hour after injection) is comparable to that of Exendin-9-39.

[0151] To further verify the conclusions of this experiment, the effects of a single injection were observed 24 hours later. Figure 11 As shown, 20 SUR1-KO mice (male to female ratio 1:1) were subcutaneously injected with Exendin-9-39 and AR-GLP1R-01 after their basal (untreated) blood glucose levels were measured. The dosage of both was 216 pM / g body weight. Blood glucose levels were observed at 16 hours and 24 hours after drug administration. The short-term effect of Exendin-9-39 in raising blood glucose could not be maintained for 16 and 24 hours, but the effect of AR-GLP1R-01 in raising blood glucose could be maintained for 24 hours after a single dose.

[0152] (II) Comparative Study of AR-GLP1R-02 and Exendin-9-39

[0153] 1. Study on the effects of Exendin-9-39 and AR-GLP1R-02 on isolated pancreatic islet function:

[0154] Figure 12 A perfusion experiment was conducted to isolate and culture islets of Langerhans, demonstrating the dynamic secretion of insulin. The stimulant was an amino acid mixture (AAM) with concentrations increasing from 0 to 12 mM; the islets were from SUR1 knockout mice. Figure 12 The results showed that SUR1-KO mice exhibited elevated basal insulin secretion and were sensitive to insulin secretion stimulated by amino acid mixtures (AAM), consistent with previous findings. 100 nM Exendin-9-39 reduced excessive basal insulin secretion and AAM-stimulated insulin secretion, also consistent with previous results. AR-GLP1R-02 (100 nM) at the same concentration had similar effects to Exendin-9-39, significantly inhibiting both basal insulin and AAM-stimulated insulin secretion. This indicates that AR-GLP1R-02 and Exendin-9-39 have similar effects, both improving the problem of excessive basal insulin secretion and excessive insulin response to amino acid stimulation caused by damage to pancreatic ATP-dependent potassium channels.

[0155] 2. Animal experimental results of Exendin-9-39 and AR-GLP1R-02:

[0156] In vivo animal studies were conducted using Exendin-9-39 and AR-GLP1R-02. The experimental design involved subcutaneous injection of Exendin-9-39 and AR-GLP1R-02 twice daily (10:00 AM and 5:00 PM) for 4 consecutive days, at a concentration of 216 pM / g body weight.

[0157] Figure 13 For in vivo experiments in SUR1-KO mice: Blood glucose changes were recorded before and 1 hour after subcutaneous injection of the drug (Exendin-9-39 or AR-GLP1R-02, dose: 216 pM / g body weight) on the first day. Figure 13 As shown, compared with the blood glucose of SUR1-KO mice that had not received any medication, Exendin-9-39 could temporarily improve blood glucose in the disease model 1 hour after injection, but blood glucose did not increase after the first dose of AR-GLP1R-02.

[0158] After 3 days of medication, compare the results before and 1 hour after medication on the 4th day (e.g., ...). Figure 14 As shown in the figure, compared with the blank solvent control group and the Exendin-9-39 treatment group, the basal blood glucose of the AR-GLP1R-02 group was comparable to that of the other two groups. The short-term effect of AR-GLP1R-02 after 1 hour of administration was consistent with that of Exendin-9-39, which could temporarily increase blood glucose in the model mice. After administration on the afternoon of day 4, the mice began the fasting test, and overnight fasting blood glucose was observed on the morning of day 5. Figure 15 As shown, after 4 days of twice-daily administration, AR-GLP1R-02 improved fasting blood glucose in the treated mouse model of the disease. This indicates that AR-GLP1R-02 is similar to Exendin-9-39, with a short-term effect (1 hour after injection) comparable to Exendin-9-39, and its effect can also be maintained after fasting, indicating that its long-term effect is superior to Exendin-9-39.

[0159] (III) Blood drug concentration detection of Exendin-9-39, AR-GLP1R-01 and AR-GLP1R-02

[0160] (1) Absorption peaks of different concentrations of Exendin-9-39, AR-GLP1R-01, and AR-GLP1R-02 standards: For Exendin-9-39, such as Figure 16 and Figure 17 As shown; for AR-GLP1R-01, as Figure 18 and Figure 19 As shown; for AR-GLP1R-02, as Figure 20 and Figure 21 As shown; a standard curve is plotted based on the chromatogram and peak area of ​​the standard.

[0161] (2) The results of blood drug concentration calculation are shown in Table 1.

[0162] The results of liquid chromatography-mass spectrometry (LC-MS) showed that the absorption peak of Exendin-9-39 occurred at approximately 4.9 minutes, while the absorption peaks of AR-GLP1R-01 and AR-GLP1R-02 occurred at approximately 7.7 minutes. Experimental mice (SUR1-KO) were subcutaneously injected with the drugs at a concentration of 216 pM / g body weight. Blood samples were collected at 0.5 hours, 2 hours, and 10 hours after administration to determine the blood drug concentration. The concentrations of the three components in serum were calculated based on the area of ​​the absorption peaks. The results show that at 0.5 h, the concentration of Exendin-9-39 in serum was lower than that of AR-GLP1R-01 and AR-GLP1R-02. Exendin-9-39 was undetectable in serum after 2 hours, but AR-GLP1R-01 and AR-GLP1R-02 were still detectable at 10 hours. This indicates that the half-lives of AR-GLP1R-01 and AR-GLP1R-02 after the side chain addition are better than those of Exendin-9-39, which also proves that this liquid chromatography-mass spectrometry method can detect the concentrations of the three samples in serum.

[0163] Table 1 Blood drug concentrations

[0164]

[0165] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any way. Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Any person skilled in the art can make some modifications or alterations to the methods and techniques disclosed above without departing from the scope of the present invention to create equivalent embodiments. Any simple modifications, equivalent changes and alterations made to the above embodiments based on the technical essence of the present invention without departing from the scope of the present invention shall still fall within the scope of the present invention.

Claims

1. The application of long-acting Exendin-9-39 in the preparation of drugs for treating hypoglycemia, characterized in that, The long-acting Exendin-9-39 is either AR-GLP1R-01 or AR-GLP1R-02; the structure of AR-GLP1R-01 is shown in formula (I), and the structure of AR-GLP1R-02 is shown in formula (II). Formula (I) Equation (II).

2. A drug for treating hypoglycemia, characterized in that, The drug contains long-acting Exendin-9-39, which is AR-GLP1R-01 or AR-GLP1R-02; the structure of AR-GLP1R-01 is shown in formula (I), and the structure of AR-GLP1R-02 is shown in formula (II). Formula (I) Equation (II).

Citation Information

Patent Citations

  • Molecular modification of GLP-1R activator, and application of dimer of GLP-1R activator in treatment of metabolic diseases

    CN111410686A

  • Long-acting GLP-1 antagonist

    CN114478744A